P7

About 13therapeutics

Founded in 2021, 13therapeutics is an early-stage biotech leveraging a peptide discovery platform to create new treatments for inflammatory conditions. The company's pipeline includes lead candidates like P13 and P7, targeting indications ranging from systemic inflammation to otitis media and noise-induced hearing loss. As a private, pre-revenue entity, it is in the research and development phase, building its scientific foundation and advancing programs toward clinical validation. Its success will hinge on translating its peptide platform into clinically effective therapies in competitive inflammatory markets.

Therapeutic Areas

Other Inflammatory Diseases (e.g., Systemic Inflammation, Hearing Loss) Drugs